Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor

Member of:

    ORCID: 0000-0003-2611-5642

    Publication year:
    All
    176 - 200 out of 236Page size: 25
    Sort by: 1st author
    1. Published

      Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

      Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In: Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    2. Published

      A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials

      Deacon, Carolyn F., Feb 2018, In: Diabetes, Obesity and Metabolism. 20, p. 34-46 13 p.

      Research output: Contribution to journal › Review › Research › peer-review

    3. Published

      Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

      Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

      Deacon, Carolyn F., 2007, In: Diabetes, Obesity and Metabolism. 9 Suppl 1, p. 23-31 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes

      Deacon, Carolyn F., Feb 2018, In: Peptides. 100, p. 150-157 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Published

      Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Advances in Therapy. 26, 5, p. 488-99 11 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    7. Published

      GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

      Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In: American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9

      Research output: Contribution to journal › Journal article › Research › peer-review

    8. Published

      Therapeutic strategies based on glucagon-like peptide 1.

      Deacon, Carolyn F., 2004, In: Diabetes. 53, 9, p. 2181-9 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    9. Published

      GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

      Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In: American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75

      Research output: Contribution to journal › Journal article › Research › peer-review

    10. Published

      Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

      Deacon, Carolyn F., 2008, In: Current Opinion in Investigational Drugs. 9, 4, p. 402-13 11 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    11. Published

      Potential of liraglutide in the treatment of patients with type 2 diabetes

      Deacon, Carolyn F., 2009, In: Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    12. Published

      Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

      Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    13. Published

      Immunoassays for the incretin hormones GIP and GLP-1

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    14. Published

      MK-431 (Merck).

      Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    15. Published

      Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

      Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    16. Published

      Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    17. Published

      Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

      Deacon, Carolyn F., Nauck, M. A., Meier, J., Hücking, K. & Holst, Jens Juul, 2000, In: Journal of Clinical Endocrinology and Metabolism. 85, p. 3575-3581

      Research output: Contribution to journal › Journal article › Research › peer-review

    18. Published

      Human colon produces fully processed glucagon-like peptide-1 (7-36 amide).

      Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: FEBS Letters. 372, p. 269-272.

      Research output: Contribution to journal › Journal article › Research › peer-review

    19. Published

      Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo.

      Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: Journal of Clinical Endocrinology and Metabolism. 80, p. 952-957

      Research output: Contribution to journal › Journal article › Research › peer-review

    20. Published

      Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

      Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278

      Research output: Contribution to journal › Journal article › Research › peer-review

    21. Published

      Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.

      Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131

      Research output: Contribution to journal › Journal article › Research › peer-review

    22. Published

      Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

      Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

      Research output: Contribution to journal › Journal article › Research › peer-review

    23. Published

      Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

      Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

      Research output: Contribution to journal › Journal article › Research › peer-review

    24. Published

      Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes

      Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170

      Research output: Contribution to journal › Journal article › Research › peer-review

    25. Published

      Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

      Deacon, Carolyn F., Wamberg, S., Bie, P., Hughes, T. E. & Holst, Jens Juul, Feb 2002, In: Journal of Endocrinology. 172, 2, p. 355-62 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    Previous 1...4 5 6 7 8 9 10 Next

    ID: 9220